Science Friday

Science Friday is a podcast and radio show produced by WNYC Studios that focuses on science and health-related topics. The content is generally well-researched, factual, and informative. However, there is a conflict of interest as they are produced by both Science Friday and WNYC Studios.

99%

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

  • > Produced by Science Friday and WNYC Studios <br> 'Alzheimer's patients can be difficult to care for, both physically and emotionally.<br> 'The cost of caring for someone with Alzheimer's disease is staggering. It can easily reach into the hundreds of thousands of dollars over a lifetime.'

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • New Evidence Suggests Modern Humans and Neanderthals Interacted for Over 200,000 Years: A Genetic Analysis of Human-Neanderthal Relationships

    New Evidence Suggests Modern Humans and Neanderthals Interacted for Over 200,000 Years: A Genetic Analysis of Human-Neanderthal Relationships

    Broke On: Thursday, 11 July 2024 Geneticists have discovered evidence of multiple waves of gene flow between modern humans and Neanderthals over a 200,000-year period, challenging previous understanding of human history and emphasizing the importance of considering diverse perspectives in scientific interpretation.
  • Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

    Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

    Broke On: Sunday, 31 March 2024 A revolutionary jab and a medication called Leqembi are undergoing trials for Alzheimer's disease. The new vaccine aims to stop damage before it occurs, while the medication slows progression in early stages of dementia. Both have mild side effects and could be widely available within five years if successful in clinical trials.